United States Senate

COMMITTEE ON FINANCE
WASHINGTON, DC 20510-6200

April 21, 2010

Via Electronic Transmission

John McCarthy
Deputy Director
Department of Health Care Finance
District of Columbia
825 North Capitol Street, NE
Washington, DC 20002

Dear Acting Director Mahaney:

In the United States, the federal and state governments spend roughly \$317 billion every year on the Medicaid program. As Ranking Member of the Senate Committee on Finance, I have an obligation to ensure that taxpayer dollars are appropriately spent on federal health care programs. Like the Medicare program, Medicaid suffers from systemic weaknesses that lead to fraud, waste, and abuse across the program, resulting in higher costs and less health care to those who are in need. The overutilization of prescription drugs, whether through drug abuse or outright fraud, plays a significant role in the rising cost of our healthcare system. The purpose of this letter is to request information regarding certain outliers in the District of Columbia's Medicaid program and what steps the District of Columbia takes to monitor rates of utilization.

In recent inquiries, I have asked the U.S. Department of Health and Human Services about physicians prescribing mental health drugs at astonishingly high rates. In addition to these concerns, a recent CNN report detailed the increasing abuse of OxyContin, Roxicodone, and Xanax. Specifically, the report described the role some pain management clinics and physicians play in the black market for these drugs. I write today to better ascertain how high rates of both mental health and pain medication utilization are affecting the Medicaid program, as well as how the District of Columbia's rates compare to the national rates.

To that end, please provide charts that list of the top ten Medicaid prescribers of the following drugs for the years 2008 and 2009. For each prescriber, please provider his/her prescriber identifier, and the number of prescriptions written per drug per year, and the total amount billed to Medicaid per drug, separated for each year.

- Abilify;
- Geodon:
- Seroquel:
- Zyprexa;
- Risperdal;

- OxyContin;
- · Roxicodone; and
- Xanax.

I thank you in advance for your cooperation and request that you provide the requested documents and written responses by no later than May 5, 2010. In your reply, please format information into a chart like the examples provided below. All formal correspondence should be sent electronically in PDF format to Brian_Downey@finance-rep.senate.gov or via facsimile to (202) 228-2131. Of course should you wish to discuss this matter further, please do not hesitate to contact Christopher Armstrong of my Committee staff at (202) 224-4515.

Sincerely,

Charles E. Grassley Ranking Member

Attachment

Drug X, 2008

Prescriber Identifier	Total prescriptions	Total billed to Medicaid
123456789	25,000	250,000
234567891	24,000	240,000
345678912	23,000	230,000
456789123	22,000	220,000
567891234	21,000	210,000
678912345	20,000	200,000
789123456	19,000	190,000
891234567	18,000	180,000
912345678	17,000	170,000
012345678	16,000	160,000
		NAME OF TAXABLE PARTY.

Drug X, 2009

Prescriber Identifier	Total prescriptions	Total billed to Medicaid
123456789	25,000	250,000
234567891	24,000	240,000
345678912	23,000	230,000
456789123	22,000	220,000
567891234	21,000	210,000
678912345	20,000	200,000
789123456	19,000	190,000
891234567	18,000	180,000
912345678	17,000	170,000
012345678	16,000	160,000
The state of the s	The same and the s	710

GOVERNMENT OF THE DISTRICT OF COLUMBIA Department of Health Care Finance



Office of the Deputy Director

Senator Charles E. Grassley United States Senate 135 Hart Senate Office Building Washington, DC 20510-1501 May 5, 2010

Dear Senator Grassley:

Please find attached the requested report on prescription medications for the District of Columbia Fee for Service Medicaid Program during calendar years 2008 and 2009. Please note that the data are reported according to National Provider Identifier (NPI) and ranked by number of prescriptions. The reports have been generated at the Health Insurance Contract Language (HICL) level and will therefore reflect brand name and generic utilization under each heading.

To monitor rates of utilization for all medications, the District of Columbia employs various methods, including monthly prescription utilization review by pharmacists as well as ongoing studies of potential fraud and abuse of the medication use system. There is also a Medicaid Drug Utilization Review board which monitors the prescribing patterns of our Medicaid providers and employs targeted interventions where appropriate.

Please do not hesitate to contact our drug utilization review pharmacist, Jamie Wilkins, Pharm.D. at 202-442-9078 or jamie.wilkins@dc.gov with any further questions.

Sincerely.

John McCarthy Deputy Director

District of Columbia Department of Health Care Finance

ENCLOSURES



Run Date:

5/5/2010

Customer ID:

DCMEDI

Drug: Abilify

Rank	National Provider Identification	Total Prescriptions	Amount Paid (Total)
1	1093851149	274	\$146,222.31
2	1033121058	139	\$60,991.70
3	1487760062	82	\$37,609.03
4	1821073776	77	\$42,543.04
5	1649317694	71	\$48,515.42
5	1891852851	71	\$37,869.56
7	1760595565	68	\$30,313.55
8	1295880003	55	\$26,614.38
9	1871634170	52	\$27,997.23
9	1992746515	52	\$26,818.39



Run Date:

5/5/2010

Customer ID:

DCMEDI

Drug: Geodon

Rank	National Provider Identification	Total Prescriptions	Amount Paid (Total)
1	1093851149	65	\$28,664.06
2	1891852851	54	\$16,068.50
3	1487760062	39	\$17,822.30
3	1871634170	39	\$15,941.30
5	1992746515	38	\$12,713.96
6	1033121058	33	\$10,919.65
6	1477587004	33	\$9,725.94
8	1649317694	32	\$14,303.76
9	1487740957	31	\$10,028.56
10	1194809640	29	\$8,724.78



Run Date:

5/5/2010

Customer ID:

DCMEDI

Drug: Oxycontin and Roxicodone

Rank	National Provider Identification	Total Prescriptions	Amount Paid (Total)
1	1215932561	63	\$15,474.66
2	1376638486	27	\$7,769.72
3	1316987787	24	\$6,432.25
4	1629022272	21	\$6,137.24
5	1053446112	20	\$3,568.10
5	1912970245	20	\$4,602.38
7	1154307866	17	\$9,494.80
8	1487850764	16	\$6,172.97
9	1114921665	15	\$641.79
9	1871527937	15	\$7,448.56
9	1992746515	15	\$2,258.41



Run Date:

5/5/2010

Customer ID:

DCMEDI

Drug: Risperdal

Rank	National Provider Identification	Total Prescriptions	Amount Paid (Total)
1	1033121058	203	\$49,564.54
. 2	1760595565	128	\$37,542.53
3	1043380140	125	\$31,578.99
4	1871634170	117	\$43,895.73
5	1063579779	107	\$45,514.95
6	1093706871	100	\$31,764.45
7	1093851149	99	\$30,623.08
8	1689868622	95	\$21,869.45
9	1992746515	91	\$24,110.86
10	1548292808	85	\$41,381.37



Run Date:

5/5/2010

Customer ID:

DCMEDI

Drug: Seroquel

Rank	National Provider Identification	Total Prescriptions	Amount Paid (Total)
1	1093851149	282	\$87,079.11
2	1033121058	228	\$59,185.49
3	1891852851	175	\$65,545.67
4	1093706871	164	\$68,621.28
5	1487740957	131	\$28,248.29
6	1992746515	126	\$48,776.05
7	1871634170	122	\$51,084.82
8	1821073776	118	\$45,285.40
9	1376633321	104	\$27,140.52
10	1487760062	99	\$50,589.05



Run Date:

5/5/2010

Customer ID:

DCMEDI

Drug: Xanax

Rank	National Provider Identification	Total Prescriptions	Amount Paid (Total)
1	1891852851	206	\$2,584.22
2	1295880003	99	\$1,042.48
3	1184702599	87	\$848.92
4	1841343977	81	\$645.15
5	1215932561	80	\$877.87
6	1508876608	60	\$677.03
7	1316987787	58	\$531.31
8	1487850764	54	\$604.97
9	1487740957	48	\$383.03
10	1760595565	46	\$4,215.79



Run Date:

5/5/2010

Customer ID:

DCMEDI

Drug: Zyprexa

Rank	National Provider Identification	Total Prescriptions	Amount Paid (Total)
1	1548292808	102	\$83,915.38
2	1093706871	99	\$53,693.70
3	1437146305	97	\$61,159.51
4	1063579779	69	\$53,206.31
4	1649317694	69	\$48,392.09
6	1821073776	66	\$40,882.95
7	1760595565	63	\$28,125.79
8	1093851149	60	\$40,572.39
9	1033121058	50	\$26,406.47
9	1477587004	50	\$26,838.76
9	1871634170	50	\$30,842.40



Run Date:

5/4/2010

Customer ID: DCMEDI

Drug: Abilify

Rank	National Provider Identification	Total Prescriptions	Amount Paid (Total)
1	1821073776	495	\$268,422.96
2	1033121058	470	\$219,730.70
3	1346398468	281	\$127,734.29
4	1487760062	215	\$110,987.12
5	1558379958	174	\$87,639.92
6	1891852851	159	\$87,373.63
7	1073761276	149	\$80,753.30
7	1144363458	149	\$93,134.06
9	1285770776	134	\$83,176.85
10	1043387236	115	\$61,979.59



Run Date: Customer ID: 5/4/2010

DCMEDI

Drug: Geodon

Rank	National Provider Identification	Total Prescriptions	Amount Paid (Total)
1	1821073776	172	\$81,203.75
2	1033121058	111	\$41,267.19
3	1992746515	90	\$34,546.61
4	1043387236	85	\$30,679.15
5	1487760062	76	\$36,001.33
5	1891852851	76	\$23,977.84
7	1285770776	69	\$32,392.17
8	1073761276	67	\$36,275.06
9	1194809640	45	\$19,016.03
10	1316089642	43	\$14,635.13
10	1942342399	43	\$12,771.54



Run Date:

5/4/2010

Customer ID:

DCMEDI

Drug: Oxycontin and Roxicodone

Rank	National Provider Identification	Total Prescriptions	Amount Paid (Total)
1	1215932561	191	\$50,539.07
2	1376638486	64	\$19,307.48
3	1629022272	54	\$13,900.16
4	1114045341	52	\$9,262.28
5	1275696015	51	\$5,712.38
6	1730255977	49	\$9,720.76
7	1144374422	42	\$8,377.22
8	1316987787	38	\$10,136.46
9	1487850764	36	\$19,230.96
10	1396825378	33	\$4,874.40
10	1912970245	33	\$8,515.98



Run Date:

5/4/2010

Customer ID:

DCMEDI

Drug: Risperdal

Rank	National Provider Identification	Total Prescriptions	Amount Paid (Total)
	A STATE OF THE PART OF THE PAR		41
. 1	1346398468	372	\$38,629.37
2	1033121058	320	\$43,148.23
3	1255486221	280	\$44,462.06
4	1558379958	243	\$38,991.77
5	1821073776	232	\$31,302.16
6	1063579779	230	\$47,862.23
7	1043380140	226	\$33,217.08
8	1992746515	148	\$26,131.26
9	1285770776	135	\$19,200.54
10	1487760062	133	\$21,281.77



Run Date:

5/4/2010

Customer ID:

DCMEDI

Drug: Seroquel

Rank	National Provider Identification	Total Prescriptions	Amount Paid (Total)
1	1821073776	507	\$192,570.94
2	1033121058	505	\$146,807.23
3	1891852851	362	\$181,566.06
4	1285770776	257	\$97,030.98
5	1073761276	255	\$73,992.60
6	1992746515	225	\$92,526.49
7	1376633321	212	\$71,548.81
8	1487760062	205	\$109,403.73
9	1942342399	203	\$85,876.81
10	1063579779	200	\$120,381.34



Run Date:

5/4/2010

Customer ID: DCMEDI

Drug: Xanax

Rank	National Provider Identification	Total Prescriptions	Amount Paid (Total)
1	1891852851	409	\$5,152.60
2	1184702599	191	\$1,768.33
3	1295880003	168	\$1,833.99
4	1215932561	145	\$1,628.85
5	1841343977	136	\$998.50
6	1316987787	110	\$987.22
7	1508876608	97	\$1,074.04
8	1487760062	77	\$861.10
9	1427115104	76	\$527.65
10	1033121058	72	\$544.77
10	1992746515	72	\$745.52



Run Date:

5/4/2010

Customer ID: DCMEDI

Drug: Zyprexa

Rank	National Provider Identification	Total Prescriptions	Amount Paid (Total)
1	1821073776	254	\$181,498.77
2	1033121058	222	\$134,658.95
3	1063579779	170	\$134,219.80
4	1255486221	164	\$72,890.16
5	1093706871	154	\$66,481.02
6	1437146305	126	\$81,255.75
7	1700965027	124	\$44,890.11
8	1376633321	103	\$85,830.98
9	1912959073	100	\$60,300.09
10	1073761276	99	\$80,883.44

PATRICK J. LEAHY, VERMONT, CHAIRMAN

HERB KOHL, WISCONSIN
DIANNE FEINSTEIN, CALIFORNIA
CHARLES E. SCHUMER. NEW YORK
RICHARD J. DURBIN, ILLINOIS
SHELDON WHITEHOUSE, RHODE ISLAND
AMY KLOBUCHAR, MINNESOTA
AL FRANKEN, MINNESOTA
CHRISTOPHER A. COONS, DELAWARE
RICHARD BLUMENTHAL, CONNECTICUT

CHARLES E. GRASSLEY, IOWA
ORRIN G. HATCH, UTAH
JON KYL, ARIZONA
JEFF SESSIONS, ALABAMA
LINDSEY O. GRAHAM, SOUTH CAROLINA
JOHN CORNYN, TEXAS
MICHAEL S. LEE, UTAH
TOM COBURN, OKLAHOMA



COMMITTEE ON THE JUDICIARY WASHINGTON, DC 20510-6275

BRUCE A. COHEN, Chief Counsel and Staff Director KOLAN L. DAVIS, Republican Chief Counsel and Staff Director

January 23, 2012

VIA ELECTRONIC TRANSMISSION

John McCarthy
Deputy Director
Department of Health Care Finance
899 North Capitol Street, NE, Suite 6037
Washington, DC 20002

Dear Mr. McCarthy:

On May 5, 2010, the Department of Health Care Finance provided my office with data regarding the top ten prescribers of several pain management and mental health drugs in your state. These types of drugs have addictive properties, and the potential for fraud and abuse by prescribers and patients is extremely high. Mental health drugs continue to be prescribed at astounding rates and pain management clinics are turning into a hotbed for black market painkillers. When these drugs are prescribed to Medicaid patients, it is the American people who pay the price for over-prescription, abuse, and fraud.

After an extensive review of prescribing habits of the serial prescribers of pain and mental health drugs in Washington, DC, I have concerns about the oversight and enforcement of Medicaid abuse in the District of Columbia. While I am sensitive to the concerns of misinterpretation of the data you provided, the numbers themselves are quite shocking.

For example, three medical providers wrote a combined 403 prescriptions for Abilify in Calendar year 2008 at a cost of \$215,583.43 to Medicaid. This accounts for more than 44 percent of the total amount prescribed in the District by the ten most

prolific prescribers of Abilify. One of these providers followed up in calendar year 2009 by leading in prescribing Abilify, Geodon, Seroquel, and Zyprexa with a cost to Medicaid of \$268, 422.96, \$81, 203.75, \$192, 570.94, and \$181, 498.77, respectively. This provider's number of prescriptions for Abilify rose from 77 to 495 from 2008 to 2009.

It is my intention to ensure that each of the states, along with the District of Columbia, is adequately monitoring, investigating, and stopping fraud and overprescription of these types of drugs. Therefore, please provide answers to the following questions:

- 1. What action, if any, has your agency taken with respect to the prescribers identified to the Committee?
- 2. If there has been no action taken with respect to these prescribers, please explain why not.
- 3. Please identify which of the providers identified to the Committee remain eligible to bill the Medicaid Program.
- 4. Please provide the 2010 and 2011 numbers for the top prescribers of these same drugs.
- 5. Has each of these prescribers been cross-checked for complaints or misconduct with the state medical board or the National Practitioner Data Bank? If not, do you plan to do so?
- 6. Have any of the prescribers identified to this Committee been referred to the District medical board?
- 7. Is there any system set up in the District to identify and monitor excessive prescription writing? If not, why not?
- 8. Have you received any training or guidance from the Centers for Medicare and Medicaid Studies to help identify potential issues with prescription drugs?
- 9. Does the District maintain a database of all prescribed controlledsubstances? If so, what entities have access to it?
- 10. Does the District have any point-of-sale restrictions related to maximum units, prior authorization, therapeutic duplication, or early refill? If not, why not?
- 11. Were any of these top ten prescribers identified in the federal-mandated Drug Utilization Review or CMS-base retrospective reviews?
- 12. Does the District have any programs in place to educate providers about the prescription of antipsychotics to children and adolescents?

Thank you in advance for your cooperation and attention in this matter. When responding to this letter, please number your answers in accordance with my questions. I would appreciate a response by February 13, 2012. If you have any questions, please do not hesitate to contact Erika Smith of my staff at (202) 224-5225.

Sincerely,

Charles E. Grassley

Church Grandey

Ranking Member

Committee on the Judiciary

GOVERNMENT OF THE DISTRICT OF COLUMBIA Department of Health Care Finance

Office of the Deputy Director



MAR 0 2 2012

Senator Charles E. Grassley United States Senate Committee on the Judiciary Washington, DC 20510-6275

Dear Senator Grassley:

Please find attached the requested report on prescription medications for the District of Columbia Fee for Service Medicaid Program for calendar years 2010 and 2011. Please note that the data are reported according to National Provider Identifier (NPI) and ranked by number of prescriptions. The reports have been generated at the Health Insurance Contract Language (HICL) level and therefore reflect brand name and generic utilization under each heading.

The responses to your questions regarding the monitoring and oversight procedures in place to detect and avoid prescription misuse and abuse within the District Medicaid program are provided in a separate document accompanying this letter.

Please do not hesitate to contact Charlene Fairfax, RPh, Senior Pharmacist at 202-442-9076 or charlene.fairfax@dc.gov with any additional questions.

Sincerely,

Linda Elam, PhD Medicaid Director

DISTRICT OF COLUMBIA

RESPONSES TO SENATOR GRASSLEY'S LETTER DATED JANUARY 23, 2012

What action, if any, has your agency taken with respect to the prescribers identified to the Committee?

• Although it is unclear the extent to which the supplied data represents clinically inappropriate care, the identified prescribers were referred to the Office of Program Integrity for further analysis and appropriate follow-up.

If there has been no action taken with respect to these prescribers, please explain why not.

 As above, the identified prescribers were referred for further analysis and followup.

Please identify which of the providers identified to the Committee remain eligible to bill the Medicaid Program.

• All identified prescribers remain eligible Medicaid providers at this time.

Please provide the 2010 and 20111 numbers for the top prescribers of these same drugs.

• Please see the two (2) attachments

Has each of these prescribers been cross checked for complaints or misconduct with the state medical board or the National Practitioner Data Bank? If not, do you plan to do so?

• This process is being conducted by the Office of Program Integrity and is currently in progress.

Have any of the prescribers identified to this Committee been referred to the District medical board?

We are requesting clarification: Is the question asking whether the District
Medicaid agency has referred any of the identified prescribers to the Board of
Medicine? If so, the answer is not at this time. Any appropriate action will follow
the completion of Office of Program Integrity review. If the question is whether
any party has referred any of the identified prescribers to the Board of Medicine,
the Medicaid program is unable to provide a response on internal proceedings of
the Board.

Is there any system set up in the District to identify and monitor excessive prescription writing? If not, why not?

DISTRICT OF COLUMBIA

RESPONSES TO SENATOR GRASSLEY'S LETTER DATED JANUARY 23, 2012

 The Medicaid program utilizes point of sale edits to identify excessive utilization by beneficiaries. The District employs several processes to monitor for prescribing patterns, including patient profile reviews by the Drug Utilization Review Board and pharmacy claims analyses conducted by the Utilization Management unit within the Office of Program Integrity.

Have you received any training or guidance from the Centers for Medicare and Medicaid Studies to help identify potential issues with prescription drugs?

 The federal Medicaid Integrity Program which sends auditors to review Medicaid claims and provider practices has identified several algorithms to detect and address outlier prescribing patterns.

Does the District maintain a database of all prescribed controlled substances? If so, what entities have access to it?

• The District of Columbia City Council has introduced legislation to establish a database of all controlled substance prescriptions filled in the District.

Does the District have any point of sale restrictions related to maximum units, prior authorization, therapeutic duplication, or early refill? If not, why not?

• The District's Pharmacy Benefit Manager utilizes point of sale edits during the pharmacy claims adjudication process to address limits on maximum units, prior authorization, therapeutic duplication and early refills.

Were any of these top ten prescribers identified in the federal mandated Drug Utilization Review or CMS-base retrospective reviews?

• Yes

Does the District have any programs in place to educate providers about the prescription of antipsychotics to children and adolescents?

- The District of Columbia Board of Pharmacy plans to implement an academic
 detailing program that is intended to educate providers on treatment guidelines
 and clinical best practices. The Board of Pharmacy solicited input from the
 Medicaid program on medication utilization patterns and had identified
 antipsychotic drug use as a topic to be addressed.
- The Department of Health Care Finance is participating in the Center for Health Care Strategies, Inc. "Improving the Use of Psychotropic Medication Among

DISTRICT OF COLUMBIA

RESPONSES TO SENATOR GRASSLEY'S LETTER DATED JANUARY 23, 2012

Children and Youth in Foster Care." The three year quality improvement initiative is focused on improving the prescribing practices of psychotropic medications among children and youth in foster care. This is a joint effort with the DC Department of Mental Health and the Child and Family Services Agency.



Customer ID: DCMEDI Run Date: 2/10/2012

Drug: Abilify

\$133, 557.96 \$295, 255.90 \$169,063.62 \$94, 807.79 \$82, 338.52 \$44, 323.83 Amount Paid (Total) \$102, 778.31 \$62, 163.97 \$32, 172.61 \$52, 373.31 **Total Prescriptions** 298 22 147 --94 58 227 181 137 National Provider Identification 1093851149 1821073776 1568622728 1366618746 1063579779 1033121058 1285770776 1679523799 1871852851 1376633321 Rank 10 N 3 4 S 9 7 œ 6



Run Date: 2/10/2012 Customer ID: DCMEDI

Drug: Geodon

≀ank	National Provider Identification Total Prescriptions Amount Paid (Total)	Total Prescriptions	Amount Paid (Total)
-	1093851149	290	\$133, 109.16
2	1821073776	115	\$60, 085.23
က	1033121058	106	\$41, 198.93
4	1891852851	78	\$33, 014.98
5	1366618746	71	\$31, 603.59
9	1568622728	99	\$31, 054.84
7	1679523799	47	\$26, 671.01
80	1063579779	46	\$28, 955.00
6	1285770776	40	\$20,086.78
10	1376633321	7	\$3, 239.05



Customer ID: DCMEDI Run Date: 2/10/2012

Drug: Oxycontin and Roxicodone

Rank	Rank National Provider Identification	Total Prescriptions	Total Prescriptions Amount Paid (Total)
-	1215932561	342	\$64, 498.10
7	1376638486	107	\$37, 085.82
3	1275696015	100	\$9, 254.18
4	1114045341	84	\$26, 493.73
2	1740212950	82	\$33, 572.45
9	1629022272	9/	\$20, 148.89
7	1841228947	7	\$26, 022.69
8	1871598110	22	\$12, 005.65
6	1467574038	99	\$19, 742.32
10	1316987787	53	\$13, 410.68

Rank	National Provider Identification Total Prescriptions	Total Prescriptions	Amount Paid (Total)
-	1215932561	342	\$64, 498.10
7	1376638486	107	\$37, 085.82
3	1275696015	100	\$9, 254.18
4	1114045341	84	\$26, 493.73
2	1740212950	82	\$33, 572.45
9	1629022272	9/	\$20, 148.89
7	1841228947	104.00	\$26, 022.69
8	1871598110	25	\$12, 005.65
6	1467574038	99	\$19, 742.32
10	1316987787	53	\$13, 410.68



Customer ID: DCMEDI Run Date: 2/10/2012

Drug: Risperdal

Rank	National Provider Identification	Total Prescriptions Amount Paid (Total)	Amount Paid (Total
-	1033121058	349	\$9, 383.66
2	1093851149	287	\$28, 364.54
3	1679523799	215	\$4, 784.19
4	1063579779	189	\$6,898.31
5	1285770776	175	\$8, 259.01
9	1891852851	171	\$32, 437.64
7	1821073776	146	\$3,804.23
8	1568622728	142	\$10, 862.95
6	1366618746	133	\$20,055.39
10	1376633321	84	\$1, 763.90

This message and all attachments are confidential and proprietary to ACS. Any unauthorized review, use, disclosure, or distribution prohibited.

Page 4 of 8



Customer ID: DCMEDI Run Date: 2/10/2012

Drug: Seroquel

Rank	National Provider Identification	Total Prescriptions Amount Paid (Total)	Amount Paid (Total)
T	1033121058	771	\$224, 183.38
2	1093851149	724	\$313, 916.15
3	1891852851	499	\$271, 781.20
4	1821073776	331	\$147, 811.13
5	1366618746	327	\$142, 331.61
9	1376633321	296	\$161, 096.42
7	1568622728	281	\$87, 788.55
8	1285770776	193	\$81, 965.28

This message and all attachments are confidential and proprietary to ACS. Any unauthorized review, use, disclosure, or distribution prohibited.

Page 5 of 8



Customer ID: DCMEDI Run Date: 2/10/2012

1063579779	157	\$130,058.31
1679523799	63	\$15, 602.76

Drug: Zyprexa

Rank	National Provider Identification	Total Prescriptions	Amount Paid (Total)
-	1093851149	319	\$317, 378.73
2	1063579779	252	\$224, 023.02
က	1821073776	222	\$217, 509.14
4	1033121058	191	\$132, 562.39
2	1366618746	161	\$141, 476.69

This message and all attachments are confidential and proprietary to ACS. Any unauthorized review, use, disclosure, or distribution prohibited.

Page 6 of 8



Run Date: 2/10/2012 Customer ID: DCMEDI

9	1285770776	156	\$137, 534.14
2	1891852851	117	\$81, 021.59
œ	1376633321	Σ	\$111, 561.64
6	1679523799	68	\$72, 498.80
10	1568622728	84	\$65, 292.53

Drug: Xanax

\$3, 662.24	262	1093851149	2
\$3, 520.07	414	1891852851	_
Amount Paid (Total)			

This message and all attachments are confidential and proprietary to ACS. Any unauthorized review, use, disclosure, or distribution prohibited. Page 7 of 8



Run Date: 2/10/2012 Customer ID: DCMEDI

3	4	5	9	7	8	6	10
1033121058	1285770776	1366618746	1679523799	1376633321	1063579779	1821073776	1568622728
96	80	62	24	22	18	18	က
\$547.11	\$549.24	\$7, 386.28	\$157.55	\$202.27	\$108.81	\$169.99	\$24.53



Customer ID: DCMEDI Run Date: 2/10/2012

Drug: Abilify

	Rank National Provider Identification Total Prescriptions	Total Prescriptions	Amount Paid (Total)
•	4000054440		0000
-	1093851149	438	\$200, 148.99
7	1033121058	363	\$240, 839.33
က	1346398468	304	\$148,068.58
4	1073761276	292	\$173, 202.03
2	1801919659	214	\$110, 520.06
9	1285770776	151	\$77, 915.94
۲	1376633321	125	\$ 67,823.64
8	1891852851	99	\$53, 779.17
6	1063579779	09	\$ 39,312.17
10	1821073776	41	\$305,984.44



Customer ID: DCMEDI Run Date: 2/10/2012

Drug: Geodon

Rank	National Provider Identification	Total Prescriptions	Amount Paid (Total)
•	1093851149	382	\$174, 589.55
2	1033121058	299	\$168, 805.33
3	1821073776	162	\$77, 968.10
4	1073761276	129	\$73, 630.86
2	1992746515	101	\$36, 333.89
9	1801919659	94	\$42,460.85
7	1891852851	69	\$29, 131.06
œ	1063579779	46	\$23, 258.93
9	1285770776	35	\$16, 774.67
10	1376633321	12	\$3, 209.06



Customer ID: DCMEDI Run Date: 2/10/2012

Drug: Oxycontin and Roxicodone

Rank	National Provider Identification		Total Prescriptions Amount Paid (Total)
•	1215932561	257	\$59, 934.03
2	1376638486	116	\$39, 624.82
3	1629022272	63	\$18, 550.37
4	1851524847	123	\$26, 504.75
2	1881651677	54	\$17, 210.08
9	1801953054	49	\$42, 252.51
7	1861650913	47	\$10, 513.58
æ	1114045341	45	\$8, 485.04
6	1467574038	45	\$17,097.05
10	1487850764	45	\$24, 311.53



Run Date: 2/10/2012 Customer ID: DCMEDI

Drug: Risperdal

	1346398468	335	\$14 242 EE
. 2	1093851149	289	\$19, 284.99
33	1033121058	284	\$18,043.74
4	1063579779	276	\$39, 553.75
2	1801919659	261	\$16, 152.35
9	1992792949	203	\$14, 414.82
7	1285770776	188	\$14, 761.00
æ	1821073776	178	\$11, 101.07
6	1891852851	166	\$44, 024.55
10	1376633321	136	\$5, 901.18



Customer ID: DCMEDI Run Date: 2/10/2012

Drug: Seroquel

Rank	National Provider Identification Total Prescriptions	Total Prescriptions	Amount Paid (Total)
1	1093851149	738	\$353, 230.70
2	1073761276	583	\$290, 595.94
3	1033121058	488	\$155, 402.58
4	1891852851	419	\$213, 554.94
5	1376633321	273	\$120, 917.21
9	1992746515	263	\$108, 981.61
7	1285770776	251	\$95, 969.90
œ	1801919659	228	\$66, 876.67
			Access to the second se



Run Date: 2/10/2012 Customer ID: DCMEDI

 9
 1063579779
 199
 \$117, 481.46

 10
 1346398468
 92
 \$25, 369.71

Drug: Zyprexa

Rank	National Provider Identification	Total Prescriptions	Amount Paid (Total)
-	1093851149	274	\$226.037.43
2	1821073776	255	\$193, 141.83
3	1073761276	240	\$218, 567.16
4	1063579779	197	\$153, 519.62
2	1033121058	185	\$125, 367.67



0,000			
9	1801919659	147	\$123,045.61
7	1285770776	143	\$89, 499.18
8	1376633321	121	\$99, 157.58
6	1891852851	107	\$70, 602.62
5	1346398468	26	\$19, 915.69

Run Date: 2/10/2012 Customer ID: DCMEDI

ns Amount Paid (Total)	377 \$4, 525.49	236 \$2, 512.16
Total Prescriptio	3	2
National Provider Identification	1891852851	1295880003
Rank	1	2

Drug: Xanax

This message and all attachments are confidential and proprietary to ACS. Any unauthorized review, use, disclosure, or distribution prohibited. Page 7 of 8



Customer ID: DCMEDI Run Date: 2/10/2012

106	1093851149	229	\$5, 707.70
118	1184702599	229	\$2,073.88
121	1215932561	145	\$2, 724.35
131	1316987787	107	\$1,084.60
184	1841343977	66	\$714.47
196	1992746515	95	\$1,032.55
148	1487760062	83	\$946.50
141	1417197435	80	\$553.99